CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 136 enrolled
Drug / intervention
LY2127399 +1 moredrug
Likely dose
LY2127399 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00308282
NCT00308282Phase 2Completed
CompareCT.gov

Phase II Study of Safety and Efficacy of Intravenous LY2127399 in Patients With Rheumatoid Arthritis Treated With Methotrexate

Eli Lilly and Company·interventional·Posted Mar 29, 2006·Updated Sep 10, 2019

In Brief

A Phase 2 clinical trial evaluating LY2127399 and Placebo for Arthritis, Rheumatoid. Completed, enrolled 136 participants across 14 sites.

Detailed Summary

This study is a multicenter, double-blind, study to evaluate the safety and effectiveness of treatment with LY2127399 (in addition to the standard of care treatment, methotrexate) for participants with Rheumatoid Arthritis. Participants will receive three intravenous doses of LY2127399 or placebo. Participants will participate in 10 or more visits to the study site, over 6 months. Evaluation of safety and efficacy will be conducted throughout the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesRomania
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 29, 2006
Enrollment StartMar 28, 2006
Primary CompletionJun 18, 2007
Study CompletionOct 18, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 20.3 years ago

Interventions

LY2127399drug

30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.

Placebodrug

IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.